Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
10.37
+0.02 (0.19%)
At close: Apr 24, 2026, 4:00 PM EDT
10.29
-0.08 (-0.77%)
After-hours: Apr 24, 2026, 7:55 PM EDT
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 7 analysts that cover Vir Biotechnology stock have a consensus rating of "Strong Buy" and an average price target of $19.43, which forecasts a 87.37% increase in the stock price over the next year. The lowest target is $12 and the highest is $30.
Price Target: $19.43 (+87.37%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2026.
Analyst Ratings
The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 3 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +92.86% | Mar 4, 2026 |
| Barclays | Barclays | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +189.30% | Feb 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $24 | Buy | Maintains | $20 → $24 | +131.44% | Feb 24, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $12 → $18 | Buy | Maintains | $12 → $18 | +73.58% | Feb 24, 2026 |
| Needham | Needham | Strong Buy Maintains $14 → $18 | Strong Buy | Maintains | $14 → $18 | +73.58% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
253.81M
from 68.56M
Increased by 270.22%
Revenue Next Year
102.48M
from 253.81M
Decreased by -59.62%
EPS This Year
-2.14
from -3.16
EPS Next Year
-2.33
from -2.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 305.5M | 162.4M | ||||||
| Avg | 253.8M | 102.5M | ||||||
| Low | 189.4M | 65.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 345.6% | -36.0% | ||||||
| Avg | 270.2% | -59.6% | ||||||
| Low | 176.2% | -74.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.85 | -1.87 | ||||||
| Avg | -2.14 | -2.33 | ||||||
| Low | -3.43 | -2.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.